MPI
LAB icon

Mairs & Power Inc’s Standard BioTools LAB Stock Holding History

Mairs & Power Inc’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$46K – 224
2019
Q3 		$46K Buy
+10,000
New +$78.8K ﹤0.01% 211

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mairs & Power Inc's LAB Position: Q4 2019 in Review

Mairs & Power Inc sold out of Standard BioTools (LAB) in Q4 2019, closing a stake of 10,000 shares — an estimated $46K sold.

Mairs & Power Inc first reported a position in LAB in Q3 2019 and held it in 1 quarter. The position peaked at $46K in Q3 2019. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

  • Mairs & Power Inc reported no remaining Standard BioTools position as of Q4 2019 after selling out during the quarter.
  • Mairs & Power Inc sold 10,000 Standard BioTools shares in Q4 2019, an estimated $46K.
  • Mairs & Power Inc first reported a position in Standard BioTools in Q3 2019 and held it in 1 quarter.
  • Mairs & Power Inc's Standard BioTools position peaked at $46K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Mairs & Power Inc's 13F filing for Q4 2019, filed 14 Feb 2020.